GT
PTGX icon

Glenmede Trust’s Protagonist Therapeutics PTGX Stock Holding History

Glenmede Trust’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
13,387
+4,152
+45% +$434K 0.01% 636
2026
Q1 		$973K Sell
9,235
-3,520
-28% -$312K ﹤0.01% 749
2025
Q4 		$1.11M Buy
+12,755
New +$1.04M 0.01% 704
2025
Q1 		$999K Buy
20,666
+11,713
+131% +$491K 0.01% 699
2024
Q4 		$346K Sell
8,953
-6,028
-40% -$263K ﹤0.01% 1047
2024
Q3 		$674K Sell
14,981
-525
-3% -$21.2K ﹤0.01% 837
2024
Q2 		$537K Buy
15,506
+4,055
+35% +$119K ﹤0.01% 882
2024
Q1 		$331K Buy
+11,451
New +$312K ﹤0.01% 1029

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Glenmede Trust's PTGX Position: Q2 2026 in Review

Glenmede Trust increased its Protagonist Therapeutics (PTGX) stake by 45% in Q2 2026, buying an estimated $434K and bringing the position to 13,387 shares worth $1.64M. The position accounts for 0.01% of the portfolio, ranked #636.

Glenmede Trust first reported a position in PTGX in Q1 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Glenmede Trust held 13,387 shares of Protagonist Therapeutics worth $1.64M as of Q2 2026.
  • Glenmede Trust bought 4,152 Protagonist Therapeutics shares in Q2 2026, an estimated $434K.
  • Protagonist Therapeutics made up 0.01% of Glenmede Trust's portfolio in Q2 2026, its #636 holding.
  • Glenmede Trust first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.